Announced Mon, 13 Apr · 16:38 IST
Pfizer clarifies XBRL filing discrepancy for Q2 FY26 results
Compliance View source PDF
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.2%1-day move
₹4858.00
prior close
₹4870.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.4+0.3+0.9+0.2+2.2+0.8-0.8-1.9-3.0-2.1-0.1-7.0-3.0
Up moveDown movePending
AI summary
Pfizer responded to NSE's query about discrepancies in the XBRL filing of its unaudited financial results for the quarter and half year ended September 30, 2025. The issue was a technical error — 'Reporting Quarter' was wrongly selected as 'Half Year' instead of 'Second quarter'. NSE flagged this on November 28, 2025, and Pfizer refiled the revised Integrated Filing (Financials) in XBRL format the same day. No restatement of financials was required; the correction was administrative.
Likely market impact
Routine procedural compliance matter with no impact on financials, earnings, or shareholders. No material price action expected.